MCM
NBIX icon

Mainstay Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Mainstay Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,846
Closed -$274K – 117
2020
Q3 		$274K Sell
2,846
-60
-2% -$6.94K 0.07% 99
2020
Q2 		$354K Buy
2,906
+260
+10% +$28.7K 0.1% 82
2020
Q1 		$228K Buy
2,646
+435
+20% +$42.6K 0.07% 83
2019
Q4 		$238K Sell
2,211
-965
-30% -$101K 0.05% 94
2019
Q3 		$288K Sell
3,176
-22
-0.7% -$2.06K 0.16% 84
2019
Q2 		$270K Buy
3,198
+768
+32% +$63.1K 0.14% 83
2019
Q1 		$213K Sell
2,430
-769
-24% -$64.3K 0.16% 81
2018
Q4 		$222K Sell
3,199
-1,011
-24% -$96.9K 0.16% 80
2018
Q3 		$518K Buy
4,210
+28
+0.7% +$3.18K 0.33% 67
2018
Q2 		$411K Buy
4,182
+37
+0.9% +$3.31K 0.32% 63
2018
Q1 		$343K Sell
4,145
-602
-13% -$50.8K 0.26% 70
2017
Q4 		$368K Buy
+4,747
New +$324K 0.31% 65

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mainstay Capital Management's NBIX Position: Q4 2020 in Review

Mainstay Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 2,846 shares — an estimated $274K sold.

Mainstay Capital Management first reported a position in NBIX in Q4 2017 and held it in 12 quarters. The position peaked at $518K in Q3 2018. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Mainstay Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Mainstay Capital Management sold 2,846 Neurocrine Biosciences shares in Q4 2020, an estimated $274K.
  • Mainstay Capital Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 12 quarters.
  • Mainstay Capital Management's Neurocrine Biosciences position peaked at $518K in Q3 2018.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Mainstay Capital Management's 13F filing for Q4 2020, filed 4 Mar 2021.